Sign in
RNTX Stock Price, Chart, Stats & News
Rein Therapeutics Inc.
Save
27.15M
Market cap
–
Current P/E
–
Forward P/E
RNTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 2.56% |
ROA | -243.75% |
ROE | -331.79% |
D/E | – |
Interest coverage ratio | – |
RNTX valuation
P/E | – |
P/S | – |
P/B | 1.95x |
P/CF | -1.57x |
P/FCF | -1.57x |
P/OCF | -1.57x |
PEG | -234.33x |
EV multiple | -0.60x |
About
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor.
Similar securities
Based on sector and market capitalization
Report issue